BD Pioneers New Standard in Surgical Safety with FDA-Cleared Surgiphor 1000mL for Wound Irrigation
PRNewswire (Mon, 2-Mar 6:50 AM ET)
PRNewswire (Wed, 25-Feb 4:15 PM ET)
PRNewswire (Wed, 25-Feb 8:00 AM ET)
BD to Present at Barclays 28th Annual Global Healthcare Conference
PRNewswire (Mon, 23-Feb 4:15 PM ET)
BD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency
PRNewswire (Mon, 23-Feb 6:50 AM ET)
Lanesha Minnix Named General Counsel for BD
PRNewswire (Thu, 19-Feb 4:15 PM ET)
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
PRNewswire (Tue, 10-Feb 1:00 PM ET)
Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses
PRNewswire (Mon, 9-Feb 8:40 AM ET)
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
PRNewswire (Mon, 9-Feb 8:40 AM ET)
BD's Strategic Shift and Segment Performance Drive Solid Start to Fiscal 2026
Market Chameleon (Mon, 9-Feb 2:32 AM ET)
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.
Becton Dickinson And Company trades on the NYSE stock market under the symbol BDX.
As of March 20, 2026, BDX stock price declined to $156.31 with 701,512 million shares trading.
BDX has a beta of 0.57, meaning it tends to be less sensitive to market movements. BDX has a correlation of 0.09 to the broad based SPY ETF.
BDX has a market cap of $44.46 billion. This is considered a Large Cap stock.
Last quarter Becton Dickinson And Company reported $5 billion in Revenue and $2.91 earnings per share. This beat revenue expectation by $104 million and exceeded earnings estimates by $.09.
In the last 3 years, BDX traded as high as $287.32 and as low as $156.25.
The top ETF exchange traded funds that BDX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BDX has underperformed the market in the last year with a price return of -11.6% while the SPY ETF gained +16.5%. However, in the short term, BDX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +3.2% vs -4.0% return in SPY. But in the last 2 weeks, BDX shares have been beat by the market, returning -7.4% compared to an SPY return of -4.1%.
BDX support price is $153.99 and resistance is $159.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDX shares will trade within this expected range on the day.